The erosion of traditional insulin tracking forces biowearables to pivot toward multi-analyte metabolic companionship.
To defend against the risk of GLP-1 drugs rendering standard continuous glucose monitors obsolete, manufacturers are bundling behavioral coaching and testing secondary biomarkers like ketones and potassium.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Device manufacturers are shifting toward multi-analyte metabolic companionship as core insulin tracking becomes commoditized.
Dexcom is rebuilding its product for GLP-1 users and pre-insulin patients, the companion-pivot the theme predicts as traditional insulin tracking erodes.
Abbott and Dexcom are stacking ketone and potassium analytes onto glucose sensing to stay indispensable as GLP-1s reshape metabolic care.